<?xml version="1.0" encoding="UTF-8"?><!-- This information is licensed under the Queen's Printer License of British Columbia found: www.bclaws.ca/standards/2014/QP-License_1.0.html. Please review the license terms carefully. --><act_pit xmlns:reg="http://www.gov.bc.ca/2013/legislation/regulation" xmlns:bcl="http://www.gov.bc.ca/2013/bclegislation" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:in="http://www.qp.gov.bc.ca/2013/inline" xmlns:fun="http://www.bclaws.ca/xslt/functions" xmlns:act="http://www.gov.bc.ca/2013/legislation/act" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="18035_pit" xsi:noNamespaceSchemaLocation="https://styles.qp.gov.bc.ca/media/PIT-XSD.xsd">
  <actname>Opioid Damages and Health Care Costs Recovery Act</actname>
  <yearenacted>2018</yearenacted>
  <chapter>35</chapter>
  <change section="1">
    <changenote eff="November 3, 2022">Section 1 (1) definitions of "active ingredient" and "consultant" were added by <chapnum>2022-34-1(a)</chapnum>, effective November 3, 2022 (Royal Assent).</changenote>
  </change>
  <change section="1">
    <changenote eff="November 3, 2022">Section 1 (1) definitions of "cost of health care benefits", "health care benefits", "manufacturer", "opioid product" and "opioid-related wrong" BEFORE amended by <chapnum>2022-34-1(b) to (f)</chapnum>, effective November 3, 2022 (Royal Assent).</changenote>
    <bcl:definition id="d1e44">
      <bcl:text>
        <in:term>cost of health care benefits</in:term> means the sum of</bcl:text>
      <bcl:paragraph id="d1e51">
        <bcl:num>a</bcl:num>
        <bcl:text>the present value of the total expenditure by the government for health care benefits provided for insured persons as a result of opioid-related disease, injury or illness or the risk of opioid-related disease, injury or illness, and</bcl:text>
      </bcl:paragraph>
      <bcl:paragraph id="d1e60">
        <bcl:num>b</bcl:num>
        <bcl:text>the present value of the estimated total expenditure by the government for health care benefits that could reasonably be expected to be provided for those insured persons as a result of opioid-related disease, injury or illness or the risk of opioid-related disease, injury or illness;</bcl:text>
      </bcl:paragraph>
    </bcl:definition>
    <bcl:definition id="d1e78">
      <bcl:text>
        <in:term>health care benefits</in:term> means</bcl:text>
      <bcl:paragraph id="d1e85">
        <bcl:num>a</bcl:num>
        <bcl:text>benefits as defined under the <in:doc>Hospital Insurance Act</in:doc>,</bcl:text>
      </bcl:paragraph>
      <bcl:paragraph id="d1e98">
        <bcl:num>b</bcl:num>
        <bcl:text>benefits as defined under the <in:doc>Laboratory Services Act</in:doc>,</bcl:text>
      </bcl:paragraph>
      <bcl:paragraph id="d1e111">
        <bcl:num>c</bcl:num>
        <bcl:text>benefits as defined under the <in:doc>Medicare Protection Act</in:doc>,</bcl:text>
      </bcl:paragraph>
      <bcl:paragraph id="d1e124">
        <bcl:num>d</bcl:num>
        <bcl:text>benefits as defined under the <in:doc>Pharmaceutical Services Act</in:doc>,</bcl:text>
      </bcl:paragraph>
      <bcl:paragraph id="d1e138">
        <bcl:num>e</bcl:num>
        <bcl:text>payments made by the government under the <in:doc>Continuing Care Act</in:doc>, and</bcl:text>
      </bcl:paragraph>
      <bcl:paragraph id="d1e151">
        <bcl:num>f</bcl:num>
        <bcl:text>other expenditures by the government, made directly or through one or more agents or other intermediate bodies, for programs, services, benefits or similar matters associated with disease, injury or illness;</bcl:text>
      </bcl:paragraph>
    </bcl:definition>
    <bcl:definition id="d1e222">
      <bcl:text>
        <in:term>manufacturer</in:term> means a person who manufactures or has manufactured an opioid product and a person who, in the past or currently,</bcl:text>
      <bcl:paragraph id="d1e229">
        <bcl:num>a</bcl:num>
        <bcl:text>causes, directly or indirectly, through arrangements with contractors, subcontractors, licensees, franchisees or others, the manufacture of an opioid product,</bcl:text>
      </bcl:paragraph>
      <bcl:paragraph id="d1e238">
        <bcl:num>b</bcl:num>
        <bcl:text>for any fiscal year of the person, derives at least 10% of revenues, determined on a consolidated basis in accordance with generally accepted accounting principles in Canada, from the manufacture or promotion of opioid products by that person or by other persons,</bcl:text>
      </bcl:paragraph>
      <bcl:paragraph id="d1e247">
        <bcl:num>c</bcl:num>
        <bcl:text>engages in or causes, directly or indirectly, other persons to engage in promoting an opioid product, or</bcl:text>
      </bcl:paragraph>
      <bcl:paragraph id="d1e256">
        <bcl:num>d</bcl:num>
        <bcl:text>is a trade association primarily engaged in</bcl:text>
        <bcl:subparagraph id="d1e264">
          <bcl:num>i</bcl:num>
          <bcl:text>advancing the interests of manufacturers,</bcl:text>
        </bcl:subparagraph>
        <bcl:subparagraph id="d1e273">
          <bcl:num>ii</bcl:num>
          <bcl:text>promoting an opioid product, or</bcl:text>
        </bcl:subparagraph>
        <bcl:subparagraph id="d1e282">
          <bcl:num>iii</bcl:num>
          <bcl:text>causing, directly or indirectly, other persons to engage in promoting an opioid product;</bcl:text>
        </bcl:subparagraph>
      </bcl:paragraph>
    </bcl:definition>
    <bcl:definition id="d1e293">
      <bcl:text>
        <in:term>opioid product</in:term> means any product that contains</bcl:text>
      <bcl:paragraph id="d1e300">
        <bcl:num>a</bcl:num>
        <bcl:text>a drug set out in the Schedule, or</bcl:text>
      </bcl:paragraph>
      <bcl:paragraph id="d1e309">
        <bcl:num>b</bcl:num>
        <bcl:text>a drug prescribed by regulation;</bcl:text>
      </bcl:paragraph>
    </bcl:definition>
    <bcl:definition id="d1e373">
      <bcl:text>
        <in:term>opioid-related wrong</in:term> means</bcl:text>
      <bcl:paragraph id="d1e380">
        <bcl:num>a</bcl:num>
        <bcl:text>a tort that is committed in British Columbia by a manufacturer or wholesaler and that causes or contributes to opioid-related disease, injury or illness, or</bcl:text>
      </bcl:paragraph>
      <bcl:paragraph id="d1e389">
        <bcl:num>b</bcl:num>
        <bcl:text>in an action under section 2 (1), a breach, by a manufacturer or wholesaler, of a common law, equitable or statutory duty or obligation owed to persons in British Columbia who have used or been exposed to or might use or be exposed to an opioid product;</bcl:text>
      </bcl:paragraph>
    </bcl:definition>
  </change>
  <change section="1">
    <changenote eff="November 3, 2022">Section 1 (6) BEFORE amended by <chapnum>2022-34-1(g)</chapnum>, effective November 3, 2022 (Royal Assent).</changenote>
    <bcl:subsection id="d1e698">
      <bcl:num>6</bcl:num>
      <bcl:text>For the purposes of determining the market share of a defendant for a type of opioid product sold in British Columbia, the court must calculate the defendant's market share for the type of opioid product by the following formula:</bcl:text>
      <oasis:table style="1" id="d1e706">
        <oasis:tgroup cols="3">
          <oasis:colspec colname="c1" colnum="1"/>
          <oasis:colspec colname="c2" colnum="2"/>
          <oasis:colspec colname="c3" colnum="3"/>
          <oasis:tbody>
            <oasis:trow>
              <oasis:entry colname="c1" valign="center" rowspan="3">
                <oasis:line>dms = </oasis:line>
              </oasis:entry>
              <oasis:entry colname="c2">
                <oasis:line>dm</oasis:line>
              </oasis:entry>
              <oasis:entry colname="c3" valign="center" rowspan="3">
                <oasis:line>× 100%</oasis:line>
              </oasis:entry>
            </oasis:trow>
            <oasis:trow>
              <oasis:entry colname="c2">
                <oasis:line>
                  <in:hr/>
                </oasis:line>
              </oasis:entry>
            </oasis:trow>
            <oasis:trow>
              <oasis:entry colname="c2">
                <oasis:line>MM</oasis:line>
              </oasis:entry>
            </oasis:trow>
          </oasis:tbody>
        </oasis:tgroup>
      </oasis:table>
      <oasis:table style="4" id="d1e753">
        <oasis:tgroup cols="3">
          <oasis:colspec colname="c1" colnum="1"/>
          <oasis:colspec colname="c2" colnum="2"/>
          <oasis:colspec colname="c3" colnum="3"/>
          <oasis:colspec colname="c4" colnum="4"/>
          <oasis:tbody>
            <oasis:trow>
              <oasis:entry rowspan="4" width="84">
                <oasis:line> </oasis:line>
              </oasis:entry>
              <oasis:entry colname="c2" valign="top" colspan="3">
                <oasis:line>where</oasis:line>
              </oasis:entry>
            </oasis:trow>
            <oasis:trow>
              <oasis:entry colname="c2" valign="top">
                <oasis:line>dms</oasis:line>
              </oasis:entry>
              <oasis:entry colname="c3" valign="top" align="center">
                <oasis:line> = </oasis:line>
              </oasis:entry>
              <oasis:entry colname="c4" valign="top">
                <oasis:line>the defendant's market share for the type of opioid product from the date of the earliest opioid-related wrong committed by that defendant to the date of trial;</oasis:line>
              </oasis:entry>
            </oasis:trow>
            <oasis:trow>
              <oasis:entry colname="c2" valign="top">
                <oasis:line>dm</oasis:line>
              </oasis:entry>
              <oasis:entry colname="c3" valign="top" align="center">
                <oasis:line> = </oasis:line>
              </oasis:entry>
              <oasis:entry colname="c4" valign="top">
                <oasis:line>the quantity of the type of opioid product manufactured or promoted by the defendant that is distributed or sold within British Columbia from the date of the earliest opioid-related wrong committed by that defendant to the date of trial;</oasis:line>
              </oasis:entry>
            </oasis:trow>
            <oasis:trow>
              <oasis:entry colname="c2" valign="top">
                <oasis:line>MM</oasis:line>
              </oasis:entry>
              <oasis:entry colname="c3" valign="top" align="center">
                <oasis:line> = </oasis:line>
              </oasis:entry>
              <oasis:entry colname="c4" valign="top">
                <oasis:line>the quantity of the type of opioid product manufactured or promoted by all manufacturers or wholesalers that is purchased or dispensed within British Columbia for the purpose of providing health care benefits from the date of the earliest opioid-related wrong committed by the defendant to the date of trial.</oasis:line>
              </oasis:entry>
            </oasis:trow>
          </oasis:tbody>
        </oasis:tgroup>
      </oasis:table>
    </bcl:subsection>
  </change>
  <change section="1">
    <changenote eff="November 3, 2022">Section 1 (7) was added by <chapnum>2022-34-1(h)</chapnum>, effective November 3, 2022 (Royal Assent).</changenote>
  </change>
  <change section="2">
    <changenote eff="November 3, 2022">Section 2 (1) BEFORE amended by <chapnum>2022-34-2</chapnum>, effective November 3, 2022 (Royal Assent).</changenote>
    <bcl:subsection id="d1e823">
      <bcl:num>1</bcl:num>
      <bcl:text>The government has a direct and distinct action against a manufacturer or wholesaler to recover the cost of health care benefits caused or contributed to by an opioid-related wrong.</bcl:text>
    </bcl:subsection>
  </change>
  <change section="2.1">
    <changenote eff="November 3, 2022">Section 2.1 was enacted by <chapnum>2022-34-3</chapnum>, effective November 3, 2022 (Royal Assent).</changenote>
  </change>
  <change section="3">
    <changenote eff="November 3, 2022">Section 3 (1) (part) BEFORE amended by <chapnum>2022-34-4 and 5</chapnum>, effective November 3, 2022 (Royal Assent).</changenote>
    <bcl:subsection id="d1e972">
      <bcl:num>1</bcl:num>
      <bcl:text>In an action under section 2 (1) for the recovery of the cost of health care benefits on an aggregate basis, subsection (2) of this section applies if the government proves, on a balance of probabilities, that, in respect of a type of opioid product,</bcl:text>
    </bcl:subsection>
  </change>
  <change section="4">
    <changenote eff="November 3, 2022">Section 4 (1) BEFORE amended by <chapnum>2022-34-4</chapnum>, effective November 3, 2022 (Royal Assent).</changenote>
    <bcl:subsection id="d1e1081">
      <bcl:num>1</bcl:num>
      <bcl:text>Two or more defendants in an action under section 2 (1) are jointly and severally liable for the cost of health care benefits if</bcl:text>
      <bcl:paragraph id="d1e1089">
        <bcl:num>a</bcl:num>
        <bcl:text>those defendants jointly breached a duty or obligation described in the definition of "opioid-related wrong" in section 1 (1), and</bcl:text>
      </bcl:paragraph>
      <bcl:paragraph id="d1e1098">
        <bcl:num>b</bcl:num>
        <bcl:text>as a consequence of the breach described in paragraph (a) of this subsection, at least one of those defendants is held liable in the action under section 2 (1) for the cost of those health care benefits.</bcl:text>
      </bcl:paragraph>
    </bcl:subsection>
  </change>
  <change section="4">
    <changenote eff="November 3, 2022">Section 4 (2) (part) BEFORE amended by <chapnum>2022-34-4 and 6</chapnum>, effective November 3, 2022 (Royal Assent).</changenote>
    <bcl:subsection id="d1e1108">
      <bcl:num>2</bcl:num>
      <bcl:text>For purposes of an action under section 2 (1), 2 or more manufacturers or wholesalers, whether or not they are defendants in the action, are deemed to have jointly breached a duty or obligation described in the definition of "opioid-related wrong" in section 1 (1) if</bcl:text>
    </bcl:subsection>
  </change>
  <change section="4">
    <changenote eff="November 3, 2022">Section 4 (2) (a) and (b) (part) BEFORE amended by <chapnum>2022-34-6</chapnum>, effective November 3, 2022 (Royal Assent).</changenote>
    <bcl:paragraph id="d1e1116">
      <bcl:num>a</bcl:num>
      <bcl:text>one or more of those manufacturers or wholesalers are held to have breached the duty or obligation, and</bcl:text>
    </bcl:paragraph>
    <bcl:paragraph id="d1e1125">
      <bcl:num>b</bcl:num>
      <bcl:text>at common law, in equity or under an enactment, those manufacturers or wholesalers would be held</bcl:text>
    </bcl:paragraph>
  </change>
  <change section="5">
    <changenote eff="November 3, 2022">Section 5 (c) was added by <chapnum>2022-34-7</chapnum>, effective November 3, 2022 (Royal Assent).</changenote>
  </change>
  <change section="6">
    <changenote eff="November 3, 2022">Section 6 BEFORE amended by <chapnum>2022-34-8</chapnum>, effective November 3, 2022 (Royal Assent).</changenote>
    <bcl:section id="d1e1198">
      <bcl:marginalnote>Limitation periods</bcl:marginalnote>
      <bcl:num>6</bcl:num>
      <bcl:subsection id="d1e1206">
        <bcl:num>1</bcl:num>
        <bcl:text>No action that is commenced by the government within 2 years after the coming into force of this section for the recovery of the cost of health care benefits, or for damages, alleged to have been caused or contributed to by an opioid-related wrong, is barred under the <in:doc>Limitation Act</in:doc>.</bcl:text>
      </bcl:subsection>
      <bcl:subsection id="d1e1215">
        <bcl:num>2</bcl:num>
        <bcl:text>Any action described in subsection (1) of this section for damages alleged to have been caused or contributed to by an opioid-related wrong is revived if the action was dismissed before the coming into force of this section merely because it was held by a court to be barred or extinguished by the <in:doc>Limitation Act</in:doc>.</bcl:text>
      </bcl:subsection>
    </bcl:section>
  </change>
  <change section="7">
    <changenote eff="November 3, 2022">Section 7 (2) (part) BEFORE amended by <chapnum>2022-34-9</chapnum>, effective November 3, 2022 (Royal Assent).</changenote>
    <bcl:subsection id="d1e1246">
      <bcl:num>2</bcl:num>
      <bcl:text>If the government is unable to establish which defendant caused or contributed to the use or exposure described in paragraph (b) and, as a result of a breach of a common law, equitable or statutory duty or obligation,</bcl:text>
    </bcl:subsection>
  </change>
  <change section="7">
    <changenote eff="November 3, 2022">Section 7 (3) (e) BEFORE amended by <chapnum>2022-34-6</chapnum>, effective November 3, 2022 (Royal Assent).</changenote>
    <bcl:paragraph id="d1e1321">
      <bcl:num>e</bcl:num>
      <bcl:text>the degree to which a defendant collaborated or acted in concert with other manufacturers or wholesalers in any conduct that caused, contributed to or aggravated the risk of disease, injury or illness;</bcl:text>
    </bcl:paragraph>
  </change>
  <change section="7.1">
    <changenote eff="November 3, 2022">Section 7.1 was enacted by <chapnum>2022-34-10</chapnum>, effective November 3, 2022 (Royal Assent).</changenote>
  </change>
  <change section="10">
    <changenote eff="November 3, 2022">Section 10 BEFORE amended by <chapnum>2022-34-4</chapnum>, effective November 3, 2022 (Royal Assent).</changenote>
    <bcl:section id="d1e1473">
      <bcl:marginalnote>Retroactive effect</bcl:marginalnote>
      <bcl:num>10</bcl:num>
      <bcl:text>A provision of this Act has the retroactive effect necessary to give the provision full effect for all purposes, including allowing an action to be brought under section 2 (1) arising from an opioid-related wrong, whenever the opioid-related wrong occurred.</bcl:text>
    </bcl:section>
  </change>
  <change section="Schedule">
    <changenote eff="November 3, 2022">Schedule, section 1 (part) and table heading BEFORE amended by <chapnum>2022-34-11</chapnum>, effective November 3, 2022 (Royal Assent).</changenote>
    <bcl:section id="d1e1798">
      <bcl:num>1</bcl:num>
      <bcl:text>A product that contains any of the following drugs is an opioid product for the purposes of this Act:</bcl:text>
      <oasis:table style="2" id="d1e1809">
        <oasis:tgroup cols="2">
          <oasis:colspec colname="c1" colnum="1"/>
          <oasis:colspec colname="c2" colnum="2"/>
          <oasis:tbody>
            <oasis:trow>
              <oasis:entry colname="c1" valign="top" align="center" width="300">
                <oasis:line>
                  <in:strong>Drugs containing any of the following active ingredients</in:strong>
                </oasis:line>
              </oasis:entry>
              <oasis:entry colname="c1" valign="top" align="center" width="300">
                <oasis:line>
                  <in:strong>Including but not limited to</in:strong>
                </oasis:line>
              </oasis:entry>
            </oasis:trow>
          </oasis:tbody>
        </oasis:tgroup>
      </oasis:table>
    </bcl:section>
  </change>
</act_pit>